|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plasminogen activator inhibitor ( PAI -1) is associated with excessive fibrin accumulation, thrombus formation, and atherosclerosis.
|
30371230 |
2018 |
|
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this patient, without traditional risk factors for atherosclerosis, eight mutations and polymorphisms in six different genes were identified: polymorphism of factor V Leiden (1691 GA), factor II prothrombin (20210 GA), methylenetetrahydrofolate reductase (MTHFR, 677 CT and 1298 AC), plasminogen activator inhibitor 1 (PAI-1) polymorphism 4G/5G and glycoprotein VI (GP6, 13254 TC, Ser219Pro).
|
28382527 |
2017 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Because PLG and Lp(a) associate with human CVD risk, interplay among the proteins might affect atherosclerosis by regulating cholesterol efflux from macrophages.
|
28768900 |
2017 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
A meta-analysis was carried out of all interventional studies that assessed the effects of moderate alcohol consumption on concentrations of low density lipoprotein cholesterol, high density lipoprotein cholesterol, triglycerides, apolipoprotein A I, interleukin 6, plasminogen activator inhibitor 1, fibrinogen, and other biomarkers previously found to be associated with risk of atherosclerosis.
|
28762059 |
2017 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The current review focuses on recent developments in plasmin(ogen) system activation and regulation and how dysregulation of this finely tuned system may contribute to inflammatory disease (atherosclerosis), impaired wound healing, and infection.
|
28052305 |
2017 |
|
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The intronic variant rs4252120 in the plasminogen gene (PLG) is known to be associated with aggressive periodontitis (AgP) and atherosclerosis.
|
28548211 |
2017 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
PLG is the third replicated shared genetic risk factor of atherosclerosis and periodontitis.
|
25466412 |
2015 |
|
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Recently, plasma soluble urokinase plasminogen activator receptor (suPAR) has gained interest as a marker of cardiovascular risk. suPAR is released through the cleavage of urokinase plasminogen activator receptor (uPAR), which is found in monocytes, activated T-lymphocytes and endothelial cells, all involved in atherosclerosis. suPAR levels have been well studied in plasma, but no studies have focused on suPAR in human atherosclerotic plaques.
|
23150653 |
2012 |
|
Arteriosclerosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, we aimed to investigate the effect of tPA (tissue plasminogen activator) and PAI-1 (plasminogen activator inhibitor) antigen concentrations and 4G/5G polymorphism of the PAI-1 gene on the development of atherosclerosis in SLE patients.
|
21719525 |
2011 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used genetically modified, atherosclerosis-prone mice, including mice with macrophage-specific uPA overexpression and mice genetically deficient in uPAR to elucidate mechanisms of uPA/uPAR/plasminogen-accelerated atherosclerosis and aneurysm formation.
|
21536666 |
2011 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plasminogen activator inhibitor type-1 (PAI-1) has already been associated with atherosclerosis; myocardial infarction; and cardiovascular disease risk factors such as obesity, insulin resistance, and dyslipidemia.
|
20127289 |
2010 |
|
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Mechanistically, elevated Lp(a) levels may either induce a prothrombotic/anti-fibrinolytic effect as apolipoprotein(a) resembles both plasminogen and plasmin but has no fibrinolytic activity, or may accelerate atherosclerosis because, like LDL, the Lp(a) particle is cholesterol-rich, or both.
|
20965889 |
2010 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Human plasminogen kringle 1-5 reduces atherosclerosis and neointima formation in mice by suppressing the inflammatory signaling pathway.
|
19874473 |
2010 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overexpression of plasminogen activator inhibitor-1 (SERPINE1, PAI-1), the major physiological inhibitor of pericellular plasmin generation, is a significant causative factor in the progression of vascular disorders (e.g. arteriosclerosis, thrombosis, perivascular fibrosis) as well as a biomarker and a predictor of cardiovascular-disease associated mortality.
|
19132220 |
2008 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Plasminogen activator inhibitor type 1 (PAI-1) is a major physiologic regulator of the fibrinolytic system and has recently gained recognition as a modulator of inflammation and atherosclerosis.
|
16968709 |
2006 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Apolipoprotein(a)-plasminogen cluster is closely related to both atherosclerosis and thrombosis, and forms a link between the two systems.
|
15905115 |
2005 |
|
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The plasminogen activation system is mostly recognized for its fibrinolytic activity but is also upregulated in chronic inflammatory diseases, including atherosclerosis and arthritis.
|
15095009 |
2004 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this paper, we have studied the contribution of the plasminogen activation system in the development of atherosclerosis by cross-breeding apoE3-Leiden mice, which have a human-like lipid profile, with mice deficient in PAI-1 (plasminogen-activator inhibitor-1), u-PA (urokinase plasminogen activator), and t-PA (tissue plasminogen activator).
|
14515193 |
2003 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Concentrations in blood of plasminogen activator inhibitor type 1 (PAI-1) and circulating free (non-esterified) fatty acids (FFA) are increased in diabetes and may accelerate atherosclerosis.
|
12669679 |
2002 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Endothelial dysfunction in patients suffering from atherosclerosis or diabetes type 2 is associated not only with suppression in release of the above mediators but also with deleterious discharge of prostaglandin endoperoxides (PGH2, PGG2), superoxide anion (O2-, peroxynitrite (ONOO-), and plasminogen activator inhibitor (PAI-1).
|
11208485 |
2001 |
|
Arteriosclerosis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found that rAN II enhanced plasmin generation on vascular endothelium in vitro and reduced thrombus formation in vivo, and concluded that enhancement of endothelial fibrinolytic activity by annexin II could modulate the hypercoagulable state of atherosclerosis.
|
11739291 |
2001 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Apo(a) that evolved from a duplicated plasminogen gene during recent primate evolution is responsible for the concentration of Lp(a) in the artery wall leading to atherosclerosis, by virtue of its ability to bind to the extracellular matrix and its role in stimulating the proliferation and migration of human smooth muscle cells.
|
11001801 |
2000 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Novel therapeutic strategy for atherosclerosis: ribozyme oligonucleotides against apolipoprotein(a) selectively inhibit apolipoprotein(a) but not plasminogen gene expression.
|
9799211 |
1998 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on the similarity of Lp(a) to both LDL and plasminogen, it has been hypothesized that the function of this unique lipoprotein may represent a link between the fields of atherosclerosis and thrombosis.
|
9915664 |
1998 |
|
Arteriosclerosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Insulin-resistant states are characterized by accelerated atherosclerosis and are associated with increased plasma concentrations of insulin and plasminogen activator inhibitor type 1 (PAI-1).
|
9386151 |
1997 |